Adimmune Corporation · TWSE:4142
Adimmune — 2024 Institutional Investors' Conference
13 slides from Adimmune's conference presentation, 2024
Slide 1: 2024 Institutional Investors' Conference
2024 TWSE: 4142 Institutional Investors’ Conference Adimmune Corporation Accelerate Vaccines into the Future
Slide 2: Disclaimer
Disclaimer • Adimmune has not released any financial forecast. Business and financial information presented in this brief and during the Q&A session, should they concern business operation or industrial development, may differ materially from actual results. These discrepancies are due to such risks
Slide 3: Agenda Overview
Agenda Overview • Company Profile • Financial Highlights for the Q3 of FY2024 • Business Outlook • Q&A
Slide 4: EMA & US FDA GMP certifications
The only influenza vaccine manufacturer in Asia with both EMA & US FDA GMP certifications Established since 1965 (60-year experience in vaccines) Chairman Chi-Shean Chan, M.D. Employees 525 (as of Nov. 2024) Total Area 38,831 square meters Products Influenza Vaccine, Enterovirus 71 Vaccine, Tetanus
Slide 5: Agenda Overview
Agenda Overview • Company Profile • Financial Highlights for the Q3 of FY2024 • Business Outlook • Q&A
Slide 6: FY2024 Q3 Consolidated Income Statement
FY2024 Q3 Consolidated Income Statement Unit：NT$ Thousands 2024.Q3 2023.Q3 Items Reviewed % Reviewed % Sales Revenues 888,242 973,345 Operating Costs (447,969) (488,399) Net operating margin 440,273 50% 484,946 50% Operating expenses (171,562) (285,873) Selling expenses (47,792) (7,585) General and
Slide 7: FY2024 Q1-Q3 Consolidated Income Statement
FY2024 Q1-Q3 Consolidated Income Statement Unit：NT$ Thousands 2024.Q1-Q3 2023.Q1-Q3 Items Reviewed % Reviewed % Sales Revenues 1,011,920 1,225,604 Operating Costs (676,959) (895,927) Net operating margin 334,961 33% 329,677 27% Operating expenses (553,604) (668,624) Selling expenses (140,920) (70,15
Slide 8: Agenda Overview
Agenda Overview • Company Profile • Financial Highlights for the Q3 of FY2024 • Business Outlook • Q&A
Slide 9: Business Outlook
Business Outlook Adimmune’s own products & CDMO 2023 2024 2025 2026 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Submission of marketing authorization & On-site inspection (scheduled) & Acquisition of marketing QIV for South Hemisphere authorization & documentation review audit in Taiwan commercial produc
Slide 10: Business Outlook: Strategic Development & New Product R&D Collaboration
Business Outlook Strategic Development & New Product R&D Collaboration •Ongoing overseas expansion of quadrivalent influenza vaccine •Southern hemisphere market (Brazil) •Middle East and South Asia •Strategic partners for new product co-development and technology transfer •Zoster vaccine (Korea) •Mi
Slide 11: Business Growth: Phase II
Business Growth: Phase II Unit：NT$ o.1 Billion Phase I Globalization Expansion Strategy Phase II Acceleration Phase II Growth Adimmune began its globalization strategy in 2015 By 2023, Adimmune Obtained the market with the acquisition of marketing authorization for its successfully completed authori
Slide 12: Q&A
Q&A
Slide 13: THANK YOU
THANK OFFICE No. 3, Sec. 1, Tanxing Rd., YOU Tanzi Dist., Taichung City 427003 , Taiwan (R.O.C.) +886-4-25381220 https://www.adimmune.com. tw/en TWSE: 4142